中文名：Selitrectinib (LOXO-195)
英文名：Selitrectinib (LOXO-195)
纯度：Moligand™，≥98%
货号：S414089
Cas号：2097002-61-2
存储温度：-20°C储存
运输条件：超低温运输
产品介绍：
Information
Selitrectinib (LOXO-195, BAY 2731954) is an orally available, highly potent, and selectiveTRK kinaseinhibitor with low nanomolar inhibitory activity against TRKA G595R, TRKC G623R, and TRKA G667C, IC50s ranging from 2.0 to 9.8 nmol/L. It is more than 1,000-fold selective for 98% of non-TRK kinases tested.
Targets
WT TRKA (Celll-free assay); TRKA G595R (Cell-free assay); TRKC G623R (Cell-free assay); WT TRKC (Cell-free assay); TRKC G696A (Cell-free assay) 31637,0.6 nM; 2 nM; 2.3 nM; 2.5 nM; 2.5 nM
In vitro
LOXO-195 potently inhibits diverse activated TRK kinases in vitro. At a concerntration of 1 μM, which is approximately 1,667-fold higher than its IC50 for TRKA (0.6 nmol/L), LOXO-195 is more than 1,000-fold selective for 98% of non-TRK kinases tested (228 individual kinases). LOXO-195 demonstrates potent inhibition of cell proliferation in TRK fusion–containing KM12, CUTO-3, and MO-91 cell lines (IC50 ≤ 5 nmol/L). In contrast, LOXO-195 treatment with concentrations up to 10 μmol/L has no inhibitory effect on the growth of the 84 cell lines that did not contain a TRK fusion.
In vivo
LOXO-195 is effective at reducing phosphorylated TRKA in tumors driven by ΔTRKA. LOXO-195 also causes inhibition of tumor growth relative to vehicle at all doses in four TRKA-dependent tumor models (NIH 3T3 ΔTRKA, ΔTRKA G595R, ΔTRKA G667C, and TPM3-NTRK1 fusion-positive KM12 colorectal cancer cells).
查看阿拉丁官网此产品相关对应页面：https://www.aladdin-e.com/zh_cn/S414089.html
关键字： 塞利替尼 (LOXO-195);BAY 2731954 ; J-515437 ; 2,4-DIFLUORO-.ALPHA.-(1H-1,2,4-TRIAZOLYL)ACETOPHENONE
上海阿拉丁生化科技股份有限公司是A股上市公司（（股票代码：688179），专注于科研试剂的研发、生产和销售，已陆续建立多个工厂和研发中心。作为领军企业，阿拉丁始终坚持质量第一，连续13年被评为“最受欢迎试剂品牌”。
阿拉丁目前常备库存试剂产品品种超过7万种，SKU总数超过46万，产品线涵盖了化学试剂、生化试剂、药靶配体、蛋白质和抗体等多个领域，是国内少数化学试剂到生物试剂全面发展的国产试剂品牌，产品同步发布在我们国内外电商平台。